Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.09T
24h Vol:
$8.59B
Dominance:
MSFT:4.90%
Stocklytics Platform
Asset logo for symbol JAZZ
Jazz Pharmaceuticals PLC
JAZZ
68
$112.91arrow_drop_up0.18%$0.21

Performance History

Chart placeholder
Key Stats
Open$112.32
Prev. Close$112.70
EPS4.83
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$6.57B
PE Ratio23.38
LOWHIGH
Day Range111.43
113.10
52 Week Range103.01
146.70
Ratios
P/B Ratio1.84
Revenue$3.83B
Operating M. %11.66%
Earnings$414.83M
Earnings Growth %285.14%
EBITDA Margin %35.81%
ROE %9.41%
EPS4.83

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

info
There's no data available for Analyst Forecast

Analyst Ratings

info
There's no data available for Analyst Ratings

Correlated Companies

PRICE$878.45
24H (%)arrow_drop_down0.55%
24H ($)-$4.88
MARKET CAP$771.28B
PRICE$497.12
24H (%)arrow_drop_down0.03%
24H ($)-$0.17
MARKET CAP$443.63B
PRICE$145.53
24H (%)arrow_drop_up0.06%
24H ($)$0.09
MARKET CAP$347.62B
PRICE$129.48
24H (%)arrow_drop_up0.08%
24H ($)$0.11
MARKET CAP$318.88B

About Jazz Pharmaceuticals PLC (JAZZ)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Bruce C. Cozadd
Headquarters
Dublin
Employees
2800
Exchange
NASDAQ
add Jazz Pharmaceuticals PLC to watchlist

Keep an eye on Jazz Pharmaceuticals PLC

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Jazz Pharmaceuticals PLC's (JAZZ) price per share?

The current price per share for Jazz Pharmaceuticals PLC (JAZZ) is $112.91. The stock has seen a price change of $0.21 recently, indicating a 0.19% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Jazz Pharmaceuticals PLC (JAZZ)?

For Jazz Pharmaceuticals PLC (JAZZ), the 52-week high is $146.7, which is 29.93% from the current price. The 52-week low is $103.01, the current price is 9.61% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Jazz Pharmaceuticals PLC (JAZZ) a growth stock?

Jazz Pharmaceuticals PLC (JAZZ) has shown an average price growth of 0.41% over the past three years. It has received a score of 34 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Jazz Pharmaceuticals PLC as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Jazz Pharmaceuticals PLC (JAZZ) stock price performance year to date (YTD)?

As of the latest data, Jazz Pharmaceuticals PLC (JAZZ) has a year-to-date price change of -11.05%. Over the past month, the stock has experienced a price change of 2.89%. Over the last three months, the change has been -6.61%. Over the past six months, the figure is -7.07%. Looking at a longer horizon, the five-year price change stands at -12.53%.

help
Is Jazz Pharmaceuticals PLC (JAZZ) a profitable company?

Jazz Pharmaceuticals PLC (JAZZ) has a net income of $414.83M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 72.78% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 11.66% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $3.83B, with a revenue growth rate of 4.78%, providing insight into the company's sales performance and growth. The gross profit is $2.79B. Operating income is noted at $659.28M. Furthermore, the EBITDA is $1.19B.

help
What is the market capitalization of Jazz Pharmaceuticals PLC (JAZZ)?

Jazz Pharmaceuticals PLC (JAZZ) has a market capitalization of $6.57B. The average daily trading volume is 804.63K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level